Fig. 5From: Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) studyRates of 100% migraine response by 4-week interval (efficacy population). †Nominal P < 0.001 vs placebo (analyses of migraine responder rates over weeks 13–24 were not formally tested per the predefined statistical hierarchy)Back to article page